MYO7A and Blindness: In one study, 50% of MYO7A patients reached legal blindness based on either VF < 20° or BCVA ≤ 0.1 at 41 years of age [18], whereas in comparison, 50% of the p.Cys870* USH2A patients in the present study experienced the same visual loss at 50 years of age.